Robeco Institutional Asset Management B.V. Buys 70,596 Shares of Incyte Co. (NASDAQ:INCY)

Robeco Institutional Asset Management B.V. increased its stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 5.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,265,966 shares of the biopharmaceutical company's stock after purchasing an additional 70,596 shares during the quarter. Robeco Institutional Asset Management B.V. owned approximately 0.66% of Incyte worth $83,680,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of Incyte by 0.9% during the first quarter. Vanguard Group Inc. now owns 22,715,821 shares of the biopharmaceutical company's stock worth $1,294,120,000 after purchasing an additional 196,440 shares during the last quarter. Acadian Asset Management LLC increased its position in Incyte by 28.0% in the 2nd quarter. Acadian Asset Management LLC now owns 3,560,989 shares of the biopharmaceutical company's stock valued at $215,833,000 after acquiring an additional 779,243 shares during the period. LSV Asset Management raised its stake in shares of Incyte by 0.5% during the second quarter. LSV Asset Management now owns 2,769,892 shares of the biopharmaceutical company's stock valued at $167,911,000 after acquiring an additional 15,115 shares during the last quarter. Pacer Advisors Inc. lifted its holdings in shares of Incyte by 17,460.4% during the second quarter. Pacer Advisors Inc. now owns 2,692,182 shares of the biopharmaceutical company's stock worth $163,200,000 after purchasing an additional 2,676,851 shares during the period. Finally, AQR Capital Management LLC grew its stake in shares of Incyte by 70.5% in the second quarter. AQR Capital Management LLC now owns 2,661,758 shares of the biopharmaceutical company's stock worth $159,905,000 after purchasing an additional 1,101,041 shares during the last quarter. Institutional investors own 96.97% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on INCY. Wells Fargo & Company raised their target price on Incyte from $62.00 to $68.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 30th. The Goldman Sachs Group increased their target price on shares of Incyte from $63.00 to $70.00 and gave the company a "neutral" rating in a research report on Wednesday, October 30th. Oppenheimer raised their price target on shares of Incyte from $81.00 to $82.00 and gave the stock an "outperform" rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. upped their price objective on shares of Incyte from $65.00 to $71.00 and gave the company a "neutral" rating in a research note on Wednesday, October 30th. Finally, StockNews.com raised shares of Incyte from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $76.74.

Incyte Stock Up 1.8 %

INCY traded up $1.37 during trading on Tuesday, hitting $77.12. 813,764 shares of the company's stock were exchanged, compared to its average volume of 2,323,871. Incyte Co. has a fifty-two week low of $50.35 and a fifty-two week high of $77.37. The stock has a market cap of $14.86 billion, a P/E ratio of 546.04, a PEG ratio of 6.68 and a beta of 0.71. The business's 50 day moving average is $66.25 and its two-hundred day moving average is $62.13. The company has a quick ratio of 1.82, a current ratio of 1.87 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY - Get Free Report) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.07 earnings per share for the quarter, missing analysts' consensus estimates of $1.19 by ($0.12). The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.08 billion. Incyte had a negative return on equity of 0.63% and a net margin of 0.80%. The company's revenue was up 23.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.91 EPS. As a group, equities analysts expect that Incyte Co. will post 0.52 earnings per share for the current fiscal year.

Insider Transactions at Incyte

In other news, insider Thomas Tray sold 572 shares of the company's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $62.94, for a total value of $36,001.68. Following the completion of the sale, the insider now owns 24,825 shares in the company, valued at $1,562,485.50. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, EVP Jonathan Elliott Dickinson sold 8,450 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $62.36, for a total transaction of $526,942.00. Following the completion of the transaction, the executive vice president now directly owns 36,390 shares of the company's stock, valued at $2,269,280.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Thomas Tray sold 572 shares of Incyte stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $62.94, for a total transaction of $36,001.68. Following the completion of the sale, the insider now directly owns 24,825 shares in the company, valued at $1,562,485.50. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 17.60% of the company's stock.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.